FDA Tackles Chemo's Cruel Side Effect: Permanent Nerve Damage
Published Date: 1/17/2025
Notice
Summary
The FDA just dropped a draft guide to help drug makers create treatments that prevent or ease nerve pain caused by chemotherapy, a tough side effect that can mess with cancer care. This affects patients battling cancer and companies developing new drugs, aiming to keep treatments on track and improve lives. Comments on this guide are open until March 18, 2025, so get your thoughts in and help shape the final rules!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA draft: Chemotherapy nerve-pain drugs
The FDA published a draft guidance to help drug and biologic sponsors develop products to prevent or treat chemotherapy-induced peripheral neuropathy (CIPN). The guidance gives recommendations on trial population, trial design, and selection of oncology-specific endpoints, and the public comment period is open until March 18, 2025. The notice also flags a safety concern that CIPN-mitigating drugs may reduce cancer treatment effectiveness or possibly promote tumor growth.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in